ARMD11
MCID: MCL032
MIFTS: 24

Macular Degeneration, Age-Related, 11 (ARMD11) malady

Categories: Genetic diseases, Eye diseases, Rare diseases, Neuronal diseases, Skin diseases

Aliases & Classifications for Macular Degeneration, Age-Related, 11

Aliases & Descriptions for Macular Degeneration, Age-Related, 11:

Name: Macular Degeneration, Age-Related, 11 54 66 13
Age Related Macular Degeneration 11 12 29
Armd11 12 66
Age-Related Macular Degeneration Type 11 69

Characteristics:

HPO:

32
macular degeneration, age-related, 11:
Inheritance polygenic inheritance


Classifications:



External Ids:

OMIM 54 611953
Disease Ontology 12 DOID:0110023
MedGen 40 C2677774
MeSH 42 D008268

Summaries for Macular Degeneration, Age-Related, 11

UniProtKB/Swiss-Prot : 66 Macular degeneration, age-related, 11: A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.

MalaCards based summary : Macular Degeneration, Age-Related, 11, also known as age related macular degeneration 11, is related to macular degeneration, age-related, 1, and has symptoms including age-related macular degeneration An important gene associated with Macular Degeneration, Age-Related, 11 is CST3 (Cystatin C). The drugs Dexamethasone and Ranibizumab have been mentioned in the context of this disorder. Affiliated tissues include eye.

Disease Ontology : 12 An age related macular degeneration conferred by variation in the CST3 gene on chromosome 20p11.

Description from OMIM: 611953

Related Diseases for Macular Degeneration, Age-Related, 11

Symptoms & Phenotypes for Macular Degeneration, Age-Related, 11

Clinical features from OMIM:

611953

Human phenotypes related to Macular Degeneration, Age-Related, 11:

32
id Description HPO Frequency HPO Source Accession
1 age-related macular degeneration 32 HP:0007868

Drugs & Therapeutics for Macular Degeneration, Age-Related, 11

Drugs for Macular Degeneration, Age-Related, 11 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2 50-02-2 5743
2
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
3
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216974-75-3
4
Verteporfin Approved, Investigational Phase 4,Phase 2 129497-78-5
5
Eplerenone Approved Phase 4,Phase 2,Phase 3 107724-20-9 150310 443872
6
Spironolactone Approved Phase 4,Phase 2,Phase 3 1952-01-7, 52-01-7 5833
7 Antiemetics Phase 4,Phase 2
8 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
9 Antineoplastic Agents, Hormonal Phase 4,Phase 2
10 Autonomic Agents Phase 4,Phase 2
11 BB 1101 Phase 4,Phase 2
12 Dexamethasone 21-phosphate Phase 4,Phase 2
13 Dexamethasone acetate Phase 4,Phase 2 1177-87-3
14 Gastrointestinal Agents Phase 4,Phase 2
15 glucocorticoids Phase 4,Phase 3,Phase 2
16 HIV Protease Inhibitors Phase 4,Phase 2
17 Hormone Antagonists Phase 4,Phase 3,Phase 2
18 Hormones Phase 4,Phase 3,Phase 2
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
20 Peripheral Nervous System Agents Phase 4,Phase 2
21
protease inhibitors Phase 4,Phase 2
22 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
23 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1
24 Pharmaceutical Solutions Phase 4
25 Antibodies Phase 4,Phase 1
26 Antibodies, Monoclonal Phase 4,Phase 1
27 Immunoglobulins Phase 4,Phase 1
28 diuretics Phase 4,Phase 2,Phase 3
29 Natriuretic Agents Phase 4,Phase 2,Phase 3
30 Endothelial Growth Factors Phase 4,Phase 3
31 Mitogens Phase 4,Phase 3
32 Diuretics, Potassium Sparing Phase 4,Phase 2,Phase 3
33 Mineralocorticoid Receptor Antagonists Phase 4,Phase 2,Phase 3
34 Mineralocorticoids Phase 4,Phase 2,Phase 3
35 Anesthetics Phase 4
36
Sulfamethazine Approved, Vet_approved Phase 3 57-68-1 5327
37
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 3 67-73-2 6215
38
Alprostadil Approved, Investigational Phase 3 745-65-3 149351
39 Platelet Aggregation Inhibitors Phase 3
40 Vasodilator Agents Phase 3
41
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177
42
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
43
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
44
Dextromethorphan Approved Phase 1, Phase 2 125-71-3 5360696 5362449
45
Guaifenesin Approved, Vet_approved Phase 1, Phase 2 93-14-1 3516
46
Acetazolamide Approved, Vet_approved Phase 2 59-66-5 1986
47
Methotrexate Approved Phase 1, Phase 2 1959-05-2, 59-05-2 126941
48
Folic Acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
49
leucovorin Approved, Nutraceutical Phase 1, Phase 2 58-05-9 54575, 6560146 143
50 Anti-Bacterial Agents Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 66)
id Name Status NCT ID Phase
1 The Endurance 1 Trial Unknown status NCT02297204 Phase 4
2 Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema Unknown status NCT02399657 Phase 4
3 Wet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab Dosing Completed NCT01453920 Phase 4
4 Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®)START Completed NCT02246829 Phase 4
5 Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD Recruiting NCT02810808 Phase 4
6 Photodynamic Therapy Versus Eplerenone: Treatment Trial for Chronic Central Serous Chorioretinopathy Recruiting NCT03079141 Phase 4
7 Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema Recruiting NCT02471651 Phase 4
8 Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety Recruiting NCT02953938 Phase 4
9 Strategies for Management of Corneal Neovascularisation Not yet recruiting NCT02594423 Phase 4
10 Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Diabetic Macular Edema (BRDME) Unknown status NCT01635790 Phase 2, Phase 3
11 SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration Completed NCT00331864 Phase 3
12 Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD Completed NCT01948830 Phase 3
13 A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD Completed NCT01436864 Phase 3
14 Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study Completed NCT01304706 Phase 3
15 Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion Recruiting NCT03108352 Phase 3
16 A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD) Not yet recruiting NCT03150589 Phase 3
17 A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Not yet recruiting NCT02215330 Phase 2, Phase 3
18 Alprostadil in Maculopathy Study (AIMS) Terminated NCT00619229 Phase 3
19 Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase Terminated NCT02032173 Phase 3
20 Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration Unknown status NCT01494805 Phase 1, Phase 2
21 Intravitreal Bevacizumab Combined With PDT Versus Bevacizumab to Treat Exudative AMD Unknown status NCT00684853 Phase 2
22 Micropulse 810 Nanomolar (nm), Diode Laser for Diffuse Diabetic Macular Edema Unknown status NCT00552435 Phase 2
23 Sirolimus for Advanced Age-Related Macular Degeneration Completed NCT01445548 Phase 1, Phase 2
24 Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD Completed NCT00574093 Phase 2
25 Pilot Study of the Evaluation of Subconjunctival Sirolimus in the Treatment of Bilateral GA Associated With AMD Completed NCT00766649 Phase 1, Phase 2
26 Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration Completed NCT00284089 Phase 1, Phase 2
27 Dextromethorphan for Diabetic Macular Edema Completed NCT01441102 Phase 1, Phase 2
28 Randomized Trial of Acetazolamide for Uveitis-Associated Cystoid Macular Edema Completed NCT00000115 Phase 2
29 Topical Interferon Gamma for Macular Edema Secondary to Uveitis Completed NCT01376362 Phase 1, Phase 2
30 A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin) Completed NCT00336323 Phase 2
31 BioCurrent Electrical Stimulation for the Treatment of Dry ARMD Recruiting NCT02699216 Phase 1, Phase 2
32 A Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients With Stargardt's Macular Degeneration Enrolling by invitation NCT01736592 Phase 1, Phase 2
33 Trientine Hydrochloride for the Prevention of Macular Edema After Cataract Surgery in Patients With Type 2 Diabetes Mellitus Not yet recruiting NCT01295073 Phase 2
34 Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD Terminated NCT01021956 Phase 2
35 Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration Terminated NCT01577381 Phase 2
36 Treatment of Non-infectious Intermediate and Posterior Uveitis Associated Macular Edema With Intravitreal Methotrexate Terminated NCT01314417 Phase 1, Phase 2
37 Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma Terminated NCT01471054 Phase 2
38 Safety & Tolerability of the IRay System in Subjects With Exudative Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) Unknown status NCT01217762 Phase 1
39 Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD) Completed NCT00109499 Phase 1
40 Palomid 529 in Patients With Neovascular Age-Related Macular Degeneration Completed NCT01271270 Phase 1
41 Efalizumab to Treat Uveitis Completed NCT00280826 Phase 1
42 Intravitreal Aflibercept Injection for Radiation Retinopathy Active, not recruiting NCT01579760 Phase 1
43 A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration Enrolling by invitation NCT01678872 Phase 1
44 Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease Terminated NCT00102115 Phase 1
45 Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration Withdrawn NCT00726466 Phase 1
46 Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME Study Withdrawn NCT00676559 Phase 1
47 Plaqenil Role in Prevention of Age Related Macular Degeneration Unknown status NCT01541449
48 A Research Study to Evaluate the Effects of Repeated Intravitreal Injections on Bacteria Around the Eye Unknown status NCT01531842
49 Living Successfully With Chronic Eye Diseases Unknown status NCT01879501
50 Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion Unknown status NCT01581151

Search NIH Clinical Center for Macular Degeneration, Age-Related, 11

Genetic Tests for Macular Degeneration, Age-Related, 11

Genetic tests related to Macular Degeneration, Age-Related, 11:

id Genetic test Affiliating Genes
1 Age-Related Macular Degeneration 11 29

Anatomical Context for Macular Degeneration, Age-Related, 11

MalaCards organs/tissues related to Macular Degeneration, Age-Related, 11:

39
Eye

Publications for Macular Degeneration, Age-Related, 11

Variations for Macular Degeneration, Age-Related, 11

UniProtKB/Swiss-Prot genetic disease variations for Macular Degeneration, Age-Related, 11:

66
id Symbol AA change Variation ID SNP ID
1 CST3 p.Ala25Thr VAR_011893 rs1064039

ClinVar genetic disease variations for Macular Degeneration, Age-Related, 11:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 CST3 NM_000099.3(CST3): c.73G> A (p.Ala25Thr) single nucleotide variant Pathogenic rs1064039 GRCh37 Chromosome 20, 23618427: 23618427

Expression for Macular Degeneration, Age-Related, 11

Search GEO for disease gene expression data for Macular Degeneration, Age-Related, 11.

Pathways for Macular Degeneration, Age-Related, 11

GO Terms for Macular Degeneration, Age-Related, 11

Sources for Macular Degeneration, Age-Related, 11

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....